Paradromics

Paradromics is building an implantable, high data‑rate brain–computer interface (BCI) designed to record activity at (or near) the single‑neuron level and translate it into speech/text and computer control. Their flagship clinical product is the Connexus® BCI, aimed first at restoring communication for people with severe motor impairment (e.g., ALS, spinal cord injury, stroke).

This brief covers the technology, clinical path, and company facts documented in public sources.

Company background

• Website: ⁰¹
• Headquarters: Austin, Texas (company press release + multiple public sources).
  • Paradromics press release (Series A / FDA breakthrough designation): ⁰²
• Company type: privately held.
• Revenue: not publicly disclosed (private company).

Funding (publicly stated / reported)

• Paradromics announced a $33M Series A led by Prime Movers Lab (with additional named investors) and tied the raise to launching first‑in‑human clinical trials.
  • Company announcement: ⁰²
  • Coverage: ⁰³

• First human implant (Jun 17, 2026): Paradromics and University of Michigan Health completed the first Connexus implant in the FDA-approved Connect-One early feasibility study. Source: ⁰⁴

• Speech (Sep 14, 2026): the company reports the first participant used Connexus for real-time speech. Source: ⁰⁵

The technology (Connexus BCI)

Paradromics describes Connexus as a fully implantable system intended for long‑term use, using materials common in medical implants (e.g., titanium alloy housing, platinum‑iridium electrodes) and miniaturized microelectrodes.

• Connexus product page (materials, form factor, high‑level system description): ⁰⁶

1) Implant architecture (as publicly described)

Paradromics describes three main implanted components:

• Cortical module (implanted under the skin; microelectrodes extend just below the brain surface)
• Internal transceiver (implanted in the chest)
• Extension lead (connects cortical module to chest transceiver)

They describe the chest transceiver as handling wireless optical data transmission to an external transceiver worn by the user, and inductive power transfer (wireless charging style) to power the implant.

• Company description of “How it works” steps: ⁰⁶

2) Channel counts + scaling strategy

Paradromics claims:

• 421 microelectrodes per cortical module

• the ability to link up to 4 implants for 1600+ intracortical channels

• Company platform description: ⁰¹

• Product page details: ⁰⁶

3) Decoding stack (software)

Paradromics describes sending data to a small computer running AI / machine learning / language models to translate neural signals into:

• text

• synthesized speech

• cursor control / device commands

• Product page: ⁰⁶

• Durability (Oct 8, 2026, company press release): Paradromics reports more than four years of stable neural recording and decoding in two sheep implanted with cortical modules described as representative of the electrode technology in the Connexus BCI. The release says spike signal-to-noise ratio stayed stable in both animals, no electrode-array migration was observed, and the animals remain healthy. A separate ongoing study of the full platform in six sheep shows stable spike SNR for nearly two years. This is preclinical, from two animals, and company-reported; no data tables were published in the release. Source: ⁰⁷

• Imaging partnership (Oct 19, 2026): Paradromics and Siemens Healthineers announced a strategic initiative to develop an end-to-end multimodal imaging workflow intended to support patient assessment, surgical planning, BCI implantation and long-term outcome monitoring. Specific imaging modalities were not disclosed in the announcement. Sources: ⁰⁸ and ⁰⁹

Clinical path (what they say is happening)

IDE approval + early feasibility study (Connect‑One)

Paradromics states the U.S. FDA granted Investigational Device Exemption (IDE) approval to begin the Connect‑One Early Feasibility Study (EFS) with Connexus.

• Company announcement: ¹⁰

They state initial enrollment begins with two participants near three clinical sites:

• UC Davis
• Massachusetts General Hospital
• University of Michigan

(Details and eligibility criteria are on their clinical study page.) ¹¹

What they’re doing recently (publicly visible milestones)

From Paradromics’ own announcements:

• IDE approval to start the Connect‑One EFS (first human clinical study with Connexus): ¹⁰
• Earlier: Breakthrough Device Designation for Connexus and a $33M raise to support first‑in‑human trials: ⁰²

How Paradromics fits in the BCI landscape (framing)

Paradromics looks like a classic “high‑bandwidth intracortical” bet:

• maximize information throughput by recording as close to neurons as possible,
• keep the device fully implantable and durable,
• focus first on a clinically defensible indication: assistive communication.

Key questions to watch

1. Signal stability over time

• Chronic single‑unit / high‑density interfaces face long‑term encapsulation and stability issues.

2. Surgical workflow + explant/upgrade path

• How invasive is implantation, and what happens when parts fail or need replacement?

3. True communication performance

• The meaningful metric is real‑world, daily use: words per minute, error rates, retraining burden, latency.

4. System bottlenecks

• Power budget, heat, data link reliability, and robust decoding under realistic conditions.